The FDA has approved changes to the drug label of the anti-seizure drug ezogabine (Potiga), underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration-all of which may become permanent.
Rose Schneider Krivich
Advertisement
Rose is the content specialist for Medical Economics.
Articles by Rose Schneider Krivich
Advertisement
Latest Updated Articles
- Anti-seizure drug gets boxed warning for eye damage risks
November 13th 2013
Advertisement
Advertisement
Trending on Modern Retina
1
Getting to the root of geographic atrophy: Diagnosis and management
2
First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy
3
Taking a step beyond low-vision aids to sharpen the focus on visual rehabilitation
4